| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 5909 | 2020 |
| Compassionate use of remdesivir for patients with severe Covid-19 J Grein, N Ohmagari, D Shin, G Diaz, E Asperges, A Castagna, T Feldt, ... New England Journal of Medicine 382 (24), 2327-2336, 2020 | 3223 | 2020 |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020 | 2534 | 2020 |
| Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells S Matsuyama, N Nao, K Shirato, M Kawase, S Saito, I Takayama, ... Proceedings of the National Academy of Sciences 117 (13), 7001-7003, 2020 | 1411 | 2020 |
| Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development M Imai, K Iwatsuki-Horimoto, M Hatta, S Loeber, PJ Halfmann, ... Proceedings of the National Academy of Sciences 117 (28), 16587-16595, 2020 | 989 | 2020 |
| Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant E Takashita, N Kinoshita, S Yamayoshi, Y Sakai-Tagawa, S Fujisaki, M Ito, ... New England Journal of Medicine 386 (10), 995-998, 2022 | 357 | 2022 |
| ACTT-1 Study Group Members JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383 (19 …, 2020 | 298 | 2020 |
| Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA. 2 E Takashita, N Kinoshita, S Yamayoshi, Y Sakai-Tagawa, S Fujisaki, M Ito, ... New England Journal of Medicine 386 (15), 1475-1477, 2022 | 281 | 2022 |
| The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner M Yamamoto, M Kiso, Y Sakai-Tagawa, K Iwatsuki-Horimoto, M Imai, ... Viruses 12 (6), 629, 2020 | 244 | 2020 |
| Multilocus sequence typing (MLST) for characterization of Enterobacter cloacae T Miyoshi-Akiyama, K Hayakawa, N Ohmagari, M Shimojima, T Kirikae PloS one 8 (6), e66358, 2013 | 231 | 2013 |
| Two cases of Zika fever imported from French Polynesia to Japan, December 2013 to January 2014 S Kutsuna, Y Kato, T Takasaki, ML Moi, A Kotaki, H Uemura, T Matono, ... Eurosurveillance 19 (4), 2014 | 226 | 2014 |
| Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug … K Matsumoto, Y Takesue, N Ohmagari, T Mochizuki, H Mikamo, M Seki, ... Journal of Infection and Chemotherapy 19, 365-380, 2013 | 222 | 2013 |
| Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA. 2 R Uraki, M Kiso, S Iida, M Imai, E Takashita, M Kuroda, PJ Halfmann, ... Nature 607 (7917), 119-127, 2022 | 215 | 2022 |
| Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 registry Japan N Matsunaga, K Hayakawa, M Terada, H Ohtsu, Y Asai, S Tsuzuki, ... Clinical Infectious Diseases 73 (11), e3677-e3689, 2021 | 211 | 2021 |
| Novel SARS-CoV-2 variant in travelers from Brazil to Japan T Fujino, H Nomoto, S Kutsuna, M Ujiie, T Suzuki, R Sato, T Fujimoto, ... Emerging infectious diseases 27 (4), 1243, 2021 | 207 | 2021 |
| First and second COVID-19 waves in Japan: a comparison of disease severity and characteristics S Saito, Y Asai, N Matsunaga, K Hayakawa, M Terada, H Ohtsu, ... The Journal of infection 82 (4), 84, 2021 | 207 | 2021 |
| Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo … H Montgomery, FDR Hobbs, F Padilla, D Arbetter, A Templeton, ... The Lancet Respiratory Medicine 10 (10), 985-996, 2022 | 206 | 2022 |
| Autochthonous dengue fever, tokyo, japan, 2014 S Kutsuna, Y Kato, ML Moi, A Kotaki, M Ota, K Shinohara, T Kobayashi, ... Emerging infectious diseases 21 (3), 517, 2015 | 200 | 2015 |
| Prolonged and late-onset symptoms of coronavirus disease 2019 Y Miyazato, S Morioka, S Tsuzuki, M Akashi, Y Osanai, K Tanaka, ... Open forum infectious diseases 7 (11), ofaa507, 2020 | 149 | 2020 |
| Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed MS Butler, V Gigante, H Sati, S Paulin, L Al-Sulaiman, JH Rex, ... Antimicrobial agents and chemotherapy 66 (3), e01991-21, 2022 | 137 | 2022 |
